Comparative Analysis of Drug Use before and after the Separate Fund Payment for Drugs Used by Outpatient in Fujian Province

doi:10.19546/j.issn.1674-3830.2022.7.017

China Health Insurance ›› 2022, Vol. 0 ›› Issue (7) : 88-92. DOI: 10.19546/j.issn.1674-3830.2022.7.017

Author information +

History +

Abstract

Objective: This study conducted an investigation on separate fund payment for drugs used by outpatient (SFPDO) in Fujian Province to further promote implementation of the policy. Methods: The data of SFPDO drugs were acquired from pharmaceutical distribution enterprises in Fujian Province from July 2020 to August 2021, and the use of 33 drugs before and after implementation of the policy was compared. Results: After the implementation of the SFPDO policy, the sales of each drug increased, indicating that the number of beneficiary patients increased. The medical expenses are saved by SFPDO. However, the growth of drug sales in different regions and different disease areas is quite different. Conclusion: SFPDO policy should be promoted and a dynamic adjustment mechanism for SFPDO policy should be established. Departments concerned should cooperate with each other to further promote the implementation of policy.

Key words

outpatient benefit / separate fund payment for drugs used by outpatient (SFPDO) / overall payment

Cite this article

EndNote

Ris (Procite)

Bibtex

Download Citations

Comparative Analysis of Drug Use before and after the Separate Fund Payment for Drugs Used by Outpatient in Fujian Province[J]. China Health Insurance. 2022, 0(7): 88-92 https://doi.org/10.19546/j.issn.1674-3830.2022.7.017

References

[1] 国家医保局,财政部.关于建立医疗保障待遇清单制度的意见(医保发〔2021〕5号)[EB/OL]. (2021-01-19) [2021-11-18] http://www.gov.cn/zhengce/zhengceku/2021-08/11/content_5630791.htm.
[2] 国务院办公厅.关于建立健全职工基本医疗保险门诊共济保障机制的指导意见(国办发〔2021〕14号)[EB/OL]. (2021-04-22) [2021-11-18] http://www.gov.cn/zhengce/zhengceku/2021-04/22/content_5601280.htm.
[3] 国家医保局.关于建立完善国家医保谈判药品“双通道”管理机制的指导意见(医保发〔2021〕 28 号) [EB/OL]. (2021-05-10) [2021-11-18] http://www.gov.cn/zhengce/2021-05/10/content_5605596.htm.
[4] 汤正明. 探讨丙肝病毒直接抗病毒药物治疗慢性丙型肝炎的疗效[J]. 医学食疗与健康,2021,19(8 ):60-61.
[5] 侯洁琼. 索非布韦联合达卡他韦对干扰素联合利巴韦林方案治疗失败丙肝患者的疗效及安全性观察[J]. 健康之友,2021,(3):74.
[6] 童陆媛,童照威,钟剑锋,等.索磷布韦、达拉他韦联合利巴韦林对基因 1b 型慢性丙肝患者 HCV RNA 转阴率的影响[J].浙江中西医结合杂志. 2019.29(9):735-737.
[7] Vallet-Pichard A, Pol S.Grazoprevir/elbasvir combination therapy for HCV infection[J]. Therap Adv Gastroenterol, 2017,10(1):155-167.
[8] 丁锦希,张静,陈烨,等.我国职工基本医疗保险个人账户发展趋势分析[J].中国医疗保险,2019(05):24-29.
[9] 谭华伟,张培林,皮星,等.我国总额预算下门诊按人头付费的模式演变、关键问题及路径优化[J].中国卫生经济,2021,40(12):20-25.
[10] 薛丽娜,王世贞,毛宗福.我国城镇职工医保的门诊统筹进展及改革思考[J].卫生经济研究,2021,38(10):30-34.
[11] 谢培轩,张慧.基于系统动力学的增强门诊共济保障功能后职工基本医疗保险基金水平预测分析[J].中国卫生经济,2021,40(09):39-43.
[12] 韩秋喜,丁锦希,付晓光,等.利益相关者视角下职工医保门诊统筹保障模式对比研究[J].卫生软科学,2021,35(10):15-18.
[13] 吴敏,时涛,韩志琰,等.山东居民医保普通门诊统筹待遇政策差异及推进省级统筹对策[J].中国农村卫生事业管理,2022,42(01):33-36.
[14] 袁晓帅. 我国基本医疗保险门诊统筹制度研究述评——基于Citespace可视化分析[J].湖北文理学院学报,2019,40(07):80-84.
[15] 伍勇,童利群.统筹支付下医保支付改革的实证分析[J].中国卫生质量管理,2020,27(01):57-60.
[16] 陈烨,丁锦希,柳婷,等.国家谈判药品门诊医保待遇现状、问题及完善措施[J].中国药科大学学报,2020,51(05):628-634.
[17] 李湘君,唐力,卞琦娟,等.某市医保统筹补偿对癌症患者门诊保障效果的研究[J].医学与社会,2020,33(07):119-123+129.
[18] 张爱琳. 城乡居民门诊统筹制度设计对医疗机构行为的影响研究[D].西南财经大学,2020.
[19] 赵斌,马勇.基层普通门诊统筹支付方式的国际经验借鉴[J].中国医疗保险,2017(11):24-29.